Quick Facts: Therapeutic Areas

• Relief of breathing difficulty associated with narrowed airways.
• Management of symptoms related to bronchial asthma.
• Supportive use in chronic obstructive pulmonary disorder (COPD).
• Prevention of breathing trouble triggered by exercise or known allergens.

---

What SalbuHEXAL Treats: Main Uses and Benefits

SalbuHEXAL contains salbutamol, a therapeutic agent indicated for managing certain respiratory conditions. Its principal use is to address bronchospasm, a condition characterized by sudden airway constriction, which may contribute to difficulties in breathing. This product is a component of a comprehensive treatment regimen for bronchial asthma in adults and pediatric patients aged four years and older with reversible obstructive airway disease. It is generally used for the symptomatic relief of acute episodes of bronchospasm.

The medication also serves a preventative role. It may be used to help prevent the onset of exercise-induced bronchospasm when administered prior to physical activity. Furthermore, it is indicated for the prevention of symptoms when an individual anticipates exposure to a known allergen or irritant that typically induces breathing difficulty. Patients may find that it supports improved ease of breathing during exacerbations of chronic obstructive pulmonary disease (COPD).

The official eligibility status for SalbuHEXAL (Salbutamol Inhalation Solution/Aerosol) is strictly defined by government regulatory documents based on age, hypersensitivity, and pre-existing medical conditions.

---

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults and Adolescents; Children aged 4 years and older (for most aerosol products) or 2 years and older (for some nebulized solutions).
Populations for whom use is contraindicated	Patients with a history of Hypersensitivity (allergy) to salbutamol or any component of the formulation. The non-intravenous solution is also contraindicated for arresting uncomplicated premature labour or threatened abortion.
Age-related eligibility rules	Safety and effectiveness of certain inhalation forms have not been established in pediatric patients younger than the minimum approved age.
Condition-specific eligibility rules	Use requires Caution in patients with pre-existing Cardiovascular Disorders (such as coronary insufficiency, arrhythmias, and hypertension), Hyperthyroidism, or Diabetes Mellitus.
Pregnancy and lactation eligibility status	Pregnancy: Use is permitted only if the expected clinical benefit justifies the potential risk to the fetus. Lactation/Breastfeeding: Use requires caution, as salbutamol may be secreted into breast milk.

---

Connection to the Overall Eligibility Profile

Regulatory documents define who can and cannot use SalbuHEXAL by establishing absolute prohibitions for patients with ingredient hypersensitivity or during certain obstetrical states. They also mandate caution for patients with specific cardiovascular, metabolic, or endocrine comorbidities, thereby constraining eligibility to population groups where the documented risks are minimized.

Interactions with other medicines and products

Official regulatory documents detail specific drug-drug interactions that must be considered during co-administration.

Products Requiring Avoidance or Special Caution

Interacting Product Category	Official Regulatory Constraint
Non-selective beta-blockers (e.g., Propranolol)	Co-administration is generally restricted due to the potential for mutual antagonism of therapeutic effects.
Xanthine derivatives, steroids, and diuretics	Concomitant use increases the patient's susceptibility to hypokalemia (low potassium levels).
Digitalis-related drugs (e.g., Digoxin)	Caution is required, as the risk of hypokalemia may increase the patient's susceptibility to cardiac arrhythmias.
Epinephrine	The drug's effects may be potentiated by concomitant use.
Diabetic Medications	Use requires care in diabetic patients, as this medication can induce a reversible rise in blood sugar (hyperglycemia).

Administration Timing Requirements

When co-administered with an inhaled corticosteroid, the official documentation states that this medication should be administered first. A short period must then elapse before the inhaled corticosteroid is used. These constraints are based on documented pharmacodynamic effects, emphasizing the need for monitoring metabolic and cardiovascular status when used alongside agents that share or amplify systemic risks.

How SalbuHEXAL Works

---

Selective Beta-2 Receptor Activation

SalbuHEXAL's mechanism is initiated by the active substance Salbutamol acting as a selective full agonist at the beta-2 (beta2) adrenergic receptors . These receptors are located predominantly on the smooth muscle cells lining the bronchial passages. The drug's rapid binding at this site triggers a molecular signal that modulates peripheral autonomic signaling within the pulmonary system.

---

Cascade for Smooth Muscle Relaxation

The activation of the beta2 receptor initiates a G-protein coupled cascade that stimulates the Adenylyl Cyclase enzyme, leading to the rapid increase of the second messenger cyclic AMP (cAMP) within the cell. The subsequent activation of Protein Kinase A (PKA) ultimately lowers the concentration of free calcium ions ( Ca^2+) inside the muscle cells. This sequence prevents the contractile process, inducing bronchial smooth muscle relaxation, which produces the physiological consequence of widening the air passages (bronchodilation).

---

Mechanism-Driven Constraints

The physiological effect is subject to constraints: the mechanism is limited to inducing reversible muscle relaxation and is not effective against permanent structural obstructions in the airways. Furthermore, excessive or persistent exposure can lead to tachyphylaxis through beta2 AR downregulation, reducing the intensity of the physiological response over time.

How to Use SalbuHEXAL: Official Administration Guidelines

The correct use of SalbuHEXAL is defined by instructions concerning administration route, dosing, frequency, and preparation. This medicine is administered via inhalation using a metered-dose aerosol inhaler or a nebuliser solution.

Dosing and Frequency

The dosage depends on the patient's age and the purpose of use, with a strict maximum limit imposed over a 24-hour period.

Administration Method	Recommended Dose	Maximum Daily Limit
Aerosol Inhaler (Adults/Children)	1 inhalation (as needed) or 2 inhalations (prevention)	Do not exceed 8 inhalations in 24 hours
Nebuliser Solution (Adults/Adolescents)	0.5 mL (5 mg), diluted, up to 4 times a day	Doses must be separated by a minimum of 4 hours

For children using the nebuliser solution, the dose is determined by body weight, with a maximum of 5 mg per single dose. For immediate relief using the aerosol inhaler, patients should wait approximately half a minute before taking a second inhalation if necessary.

Preparation and Procedure

Before using a new or unused aerosol inhaler, it must be conditioned by shaking and releasing one or two test sprays into the air. If the inhaler has been stored below 15 C, it should be warmed to room temperature before use. The nebuliser solution must be diluted with 0.9% sodium chloride solution to a final volume of 2.0 to 2.5 mL before administration. The procedural sequence involves exhaling fully, placing the mouthpiece, starting a slow inhalation simultaneously with pressing the canister, and then holding the breath for up to 10 seconds.

If a dose is missed, instructions state to take the next dose only when it is due; do not take a double dose to compensate.

Research Evidence / Overview of Studies for SalbuHEXAL

This summary outlines the types of clinical research conducted for inhaled salbutamol. It is based solely on regulatory-reviewed research and describes what the studies examined and what remains uncertain, without providing any medical guidance or making claims about expected individual results.

Evidence for Use in Acute Symptom Relief

Salbutamol was studied in research contexts involving acute breathing difficulty in conditions like asthma or Chronic Obstructive Pulmonary Disease (COPD). Researchers have explored this through a large number of short-term Randomized Controlled Trials (RCTs) and systematic reviews. These trials were designed to examine outcomes related to episodic or acute changes in the airways. Researchers typically monitored functional measures, such as the Forced Expiratory Volume in 1 second ( FEV1), to observe the potential for short-term physiological changes in lung function immediately after administration.

Evidence for Symptom Management in Chronic Respiratory Conditions

Research for contexts associated with chronic conditions comes from intermediate-term RCTs and larger, long-term observational cohorts. These studies were used in research exploring how symptoms change over time when salbutamol is used as a reliever medication in adult and adolescent populations. Studies explored outcomes capturing phases of heightened symptom activity, such as the frequency of severe exacerbations.

What is Still Uncertain: A key area examined by regulatory bodies is the pattern of high consumption of short-acting relievers like salbutamol during chronic symptoms. Some observational studies describe patterns where high consumption was associated with patterns related to increased acute exacerbations. The pattern of high long-term use has been a subject of research, as findings indicate it may be associated with patterns of symptom variability.

Studies on Preventative Use

Salbutamol was studied for research purposes in the context of Exercise-Induced Bronchospasm (EIB). The research design typically involved controlled physiological studies where individuals with known EIB were administered the medication shortly before engaging in a standardized exercise challenge. The outcomes monitored included objective measurements of lung function after the exercise, such as the FEV1, to examine post-exertional lung function. This research is specific to the acute, pre-exercise window.

Key Studies & References

1. Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines - GOV.UK
2. Salbutamol in the Management of Asthma: A Review (MDPI)

Common questions about SalbuHEXAL (FAQ)

Q: How quickly will SalbuHEXAL start working to relieve breathing problems?

SalbuHEXAL contains the active ingredient salbutamol, which functions as a fast-acting bronchodilator. According to regulatory documents, this medicine typically begins to work within a few minutes after inhalation. Regulatory documents indicate this rapid action is intended to provide quick relief for sudden symptoms of asthma and COPD.

---

Q: What should I do if my usual dose of SalbuHEXAL does not provide relief?

If your usual treatment with SalbuHEXAL does not provide adequate relief, or if your symptoms worsen, it is important to seek immediate medical advice. Official product information indicates that an increased requirement for this medicine can be a sign of your underlying condition worsening. Individuals should avoid increasing the dose beyond the recommended amount without first consulting a healthcare professional.

---

Q: Can I use SalbuHEXAL for a cough that is not related to asthma or COPD?

SalbuHEXAL is a medicine specifically used to treat breathing difficulties caused by bronchospasm, which is the tightening of airways associated with conditions like asthma and COPD. According to regulatory sources, it is not indicated for treating a regular cough or other non-respiratory symptoms. Official guidance indicates its use is generally limited to the conditions for which it has been prescribed.

---

Q: Is it safe to use SalbuHEXAL every day as a preventive measure?

SalbuHEXAL is generally used as a 'reliever' treatment, meaning it is taken when quick relief from symptoms like wheezing and shortness of breath is needed. The official product information indicates that routine, daily preventive use is typically reserved for specific situations or when advised by a doctor. If frequent use of this medication is needed, regulatory documents suggest consulting a doctor to discuss whether a daily 'preventer' medicine is appropriate.

---

Q: Can SalbuHEXAL cause me to feel shaky or have a faster heartbeat?

Yes, regulatory documents list tremors (shakiness) and tachycardia (a faster heartbeat) as common side effects of salbutamol, the active ingredient in SalbuHEXAL. These effects are related to how the medicine works on the body's systems. If these effects become severe or persistent, individuals are advised to consult their doctor regarding their treatment.

---

Q: How should I store SalbuHEXAL when I am not using it?

According to the official product information, SalbuHEXAL should be stored out of sight and reach of children. Official product information emphasizes keeping the inhaler in a cool, dry place, and away from direct heat or sunlight. The medicine should not be used past the expiration date printed on the packaging.

How to Store and Dispose of SalbuHEXAL?

SalbuHEXAL pressurised inhalation suspension must be stored at a temperature not exceeding 30 C and should be kept out of the sight and reach of children.

Storage Requirements

Due to the nature of the pressurized canister, the product must be protected from heat, direct sunlight, and frost and must not be exposed to temperatures higher than 50 C. The canister must not be pierced or burned, even when empty. If the inhaler has been stored below 0 C, it requires warming in the hands for two minutes before use to ensure stability.

Disposal Instructions

Official regulations require that unused or expired SalbuHEXAL must not be thrown away via wastewater or household waste. Disposal must adhere to local, regional, and national pharmaceutical waste regulations. Patients are instructed to ask their pharmacist for guidance on properly discarding the medicine.